Not Signed In -
EGFR |
|
|
The extracellular domain of EGFR in a complex with EGF PDB 1NQL Epidermal growth factor receptor Identifiers Symbol(s) EGFR ERBB1 Entrez 1956 OMIM 131550 RefSeq NM_005228 UniProt P00533 PDB {{{PDB}}} Other data EC number 2.7.1.112 Locus Chr. 7 p12 Epidermal growth factor receptor (EGFR) is the receptor for epidermal growth factor (EGF). It is a member of the ErbB family receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER ...
Wikipedia - [full article]
EGFR Clinical Trials
- First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
ClinicalTrials.gov Identifier: NCT00339586 - Recruiting
Lung Neoplasms; Non-Small Cell Lung Cancer; Adenocarcinoma, Bronchiolo-Alveolar
- Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
ClinicalTrials.gov Identifier: NCT00154102 - Active, not recruiting
EGFR-expressing metastatic colorectal cancer
- Oxaliplatin and Cetuximab in First-Line Treatment of mCRC
ClinicalTrials.gov Identifier: NCT00125034 - Active, not recruiting
first-line MCRC; EGFR positive; metastatic CRC
- First-Line Treatment for Adenocarcinoma Patients With EGFR Mutation
ClinicalTrials.gov Identifier: NCT00344773 - Active, not recruiting
Pulmonary Cancer
- Tarceva® as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
ClinicalTrials.gov Identifier: NCT00294762 - Active, not recruiting
Carcinoma, Non-Small-Cell Lung
- Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer
ClinicalTrials.gov Identifier: NCT00173472 - Active, not recruiting
Colorectal Cancer
- Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
ClinicalTrials.gov Identifier: NCT00298064 - Active, not recruiting
Cervical Cancer; Cervix
- Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
ClinicalTrials.gov Identifier: NCT00400374 - Recruiting
Head and Neck Cancer
- ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
ClinicalTrials.gov Identifier: NCT00404924 - Recruiting
Non-Small-Cell Lung Carcinoma
- DAHANCA 19: The Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
ClinicalTrials.gov Identifier: NCT00496652 - Recruiting
Cancer of the Head and Neck
- Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
ClinicalTrials.gov Identifier: NCT00567359 - Recruiting
Non-Small Cell Lung Cancer
- Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor in Premalignant Lesions of Head and Neck of Former Smokers
ClinicalTrials.gov Identifier: NCT00314262 - Recruiting
Precancerous Conditions
- Phase II Single Arm BIBW 2992 in NSCLC With EGFR Activating Mutations
ClinicalTrials.gov Identifier: NCT00525148 - Recruiting
Carcinoma, Non-Small-Cell Lung
- RADIANT: A Study of Tarceva After Surgery With or Without Adjuvant Chemotherapy in NSCLC Patients Who Have EGFR-Positive Tumors
ClinicalTrials.gov Identifier: NCT00373425 - Recruiting
Non-Small Cell Lung Cancer
- Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin
ClinicalTrials.gov Identifier: NCT00552149 - Recruiting
Advanced Biliary Cancer
- Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced NSCLC in Patients With Mutations in the TK Domain of EGFR
ClinicalTrials.gov Identifier: NCT00446225 - Recruiting
Non-Small Cell Lung Cancer
- Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy
ClinicalTrials.gov Identifier: NCT00343759 - Recruiting
Breast Cancer
- Cetuximab, Capecitabine and Oxaliplatin in Patients With EGFr Expressing Metastatic Colorectal Cancer
ClinicalTrials.gov Identifier: NCT00444678 - Recruiting
Colorectal Cancer; Neoplasm Metastasis
- The Role of Eriotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome
ClinicalTrials.gov Identifier: NCT00570375 - Recruiting
Myelodysplastic Syndrome
- Study Using IMC-A12 With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy
ClinicalTrials.gov Identifier: NCT00503685 - Recruiting
Colorectal Cancer
- A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
ClinicalTrials.gov Identifier: NCT00551850 - Recruiting
Advanced Cancer; Refractory Cancer
- Phase III Study of Irinotecan and Cetuximab vs Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Cancer
ClinicalTrials.gov Identifier: NCT00063141 - Active, not recruiting
Colorectal Cancer
- Pilot Study Using Neoadj Chemo-Rad & EGFR-Tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
ClinicalTrials.gov Identifier: NCT00243854 - Recruiting
Pancreatic Cancer
- Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
ClinicalTrials.gov Identifier: NCT00009841 - Active, not recruiting
lip and oral cavity cancer; Head and Neck Cancer; Oropharyngeal Cancer
- Phase III Study of Cetuximab, Oxaliplatin, 5-FU/LV vs. Oxaliplatin, 5-FU/LV in Patients with Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
ClinicalTrials.gov Identifier: NCT00061815 - Active, not recruiting
Colorectal Cancer
- High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
ClinicalTrials.gov Identifier: NCT00372515 - Recruiting
Non-Small Cell Lung Cancer
- Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
ClinicalTrials.gov Identifier: NCT00240682 - Recruiting
Skin Diseases; Carcinoma, Squamous Cell
- Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
ClinicalTrials.gov Identifier: NCT00503971 - Not yet recruiting
Non-Small Cell Lung Cancer
- Study of Erbitux (cetuximab) Given Alone to Patients with EGFR-undetectable Metastatic Colon or Rectal Cancer that is Refractory to Chemotherapy
ClinicalTrials.gov Identifier: NCT00083720 - Recruiting
Colorectal Neoplasms; Metastases; Neoplasm
- Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
ClinicalTrials.gov Identifier: NCT00063401 - Active, not recruiting
Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Neoplasms
- Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
ClinicalTrials.gov Identifier: NCT00023634 - Active, not recruiting
adult brain tumor; Gastric Cancer; ovarian epithelial cancer; Prostate Cancer
- ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT00312377 - Recruiting
Non-Small Cell Lung Cancer; Lung Cancer
- Study Evaluating HKI-272 in Tumors
ClinicalTrials.gov Identifier: NCT00146172 - Completed
HER2/neu or HER1/EGFR positive tumors
- HuMax-EGFr in Head and Neck Cancer
ClinicalTrials.gov Identifier: NCT00093041 - Completed
Head and Neck Neoplasms
- A Phase I/II Trial of an Oral mTOR Protein Kinase Inhibitor (Everolimus, RAD001) in Combination with an Oral EGFR Tyrosine Kinase Inhibitor (Erlotinib, Tarceva™) in Patients with Metastatic Breast Cancer
ClinicalTrials.gov Identifier: NCT00179270 - Recruiting
Metastatic breast cancer
- Angiogenic and EGFR Blockade with Curative Chemoradiation for Advanced Head and Neck Cancer
ClinicalTrials.gov Identifier: NCT00140556 - Recruiting
Head and Neck Cancer; Cancer of the Head and Neck; upper aerodigestive tract neoplasms; Pharynx Cancer; Pharynx Neoplasms
- MAD Refractory: Solid Tumor QD w/o Break
ClinicalTrials.gov Identifier: NCT00207012 - Completed
HER2 or EGFR Expressing Advanced Solid Malignancies
- A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-Detectable Metastatic Colorectal Carcinoma
ClinicalTrials.gov Identifier: NCT00362102 - Completed
Colorectal Carcinoma
- Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer
ClinicalTrials.gov Identifier: NCT00536614 - Completed
Pancreatic Cancer
- Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide
ClinicalTrials.gov Identifier: NCT00421694 - Completed
Prostate Cancer
- A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR
ClinicalTrials.gov Identifier: NCT00198159 - Terminated
Refractory Germ Cell Tumors Expressing EGRF
Resources
- EGFR (Lab Tests Online)
email this page
print this page
bookmark this page
feedback on this page
